Vanmusicblues: "The ability to market the Belcebo as a real diet drug is now finished.. The FDA low efficacy determination now coupled with Europe's determination it doesnt work well enough to meet their minimum requirements is devastating. After some trials maybe this will get insurance coverage for other indications"
Van, stop lying: "coupled with Europe's determination it doesn't work well enough"....we both know that you don't know what Europe said, it hasn't been made public.
If you havnt figured it out yet, van has an agenda here on these message boards. I know he claims he is just here trying to help us poor slobs, but I highly doubt that. The sooner you folks learn about the ignore button the better off you will be. Creating posts titled "VAnmusicblues..." and replying to his constant stream of half truths and lies only gives him a sense of credibility. Just let his posts slide down to the next page with no replies. Yet, I still see he makes people feel like they need to defend ARENA or defend their investment decisions. I'm not saying ignore all that have differing investment strategies but in Van's case (and plenty of others) he is merely a broken record saying the same thing over and over and over and over and over and over.
ignore is great. try it.
PS. Yes cfh64 or whatever your name is, there are also plenty of "longs" that are broken records and they too are on ignore.
emotionless, go read the ARNA disclosure filed with the financials about Europe's serious problems and weep.It is specific You should do real DD and know basic relevant information. Your response shows ignorance sadly
All, below is what I see in filings this liar is talking about:
We also filed an MAA for regulatory approval of BELVIQ in the European Union, which we subsequently decided to withdraw. In January 2013, we received the Day 180 List of Outstanding Issues from the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP, which identified major objections that needed to be addressed before the CHMP could recommend BELVIQ for marketing approval in the European Union. In accordance with the CHMP's process, we were asked to respond in writing, we were invited by the CHMP to provide an oral explanation, and we expected the CHMP to reach its final opinion at nominal Day 210, which, accounting for anticipated clock stoppages during the regulatory process, we expected to occur in the first half of 2013. Following our written response to the Day 180 List of Outstanding Issues and our April 2013 oral explanation, the CHMP's view was that certain major objections remained outstanding that precluded a recommendation for approval of the BELVIQ MAA at such time. We did not believe we could resolve the major objections related to the results of nonclinical studies prior to the time we expected the CHMP to issue its final opinion, and, therefore, we decided to withdraw the BELVIQ MAA for the European Union. We are evaluating submitting in Europe at a later date.